GlaxoSmithKline plc - Directorate Change
LONDON, Sept. 8, 2008-GlaxoSmithKline plc (GSK) today announced that Chris Viehbacher, Executive Director and President North American Pharmaceuticals, has decided to stand down from the Board on 8th September, and will leave the company with effect from 1st December 2008 to pursue another opportunity.
Andrew Witty, Chief Executive Officer said: I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavours.”
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Enquiries:
UK Media enquiries:
Philip Thomson
(020) 8047 5502
Claire Brough
(020) 8047 5502
Alice Hunt
(020) 8047 5502
Gwenan White
(020) 8047 5502
US Media enquiries:
Nancy Pekarek
(215) 751 7709
Mary Anne Rhyne
(919) 483 2839
Sarah Alspach
(215) 751 7709
European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
Sally Ferguson
(020) 8047 5543
Gary Davies
(020) 8047 5503
US Analyst/ Investor enquiries:
Frank Murdolo
(215) 751 7002
Tom Curry
(215) 751 5419
Posted: September 2008
